David Vanderveen Sells Shares of Prenetics Global Limited $PRE
Key Points
- David Vanderveen sold 8,681 shares of Prenetics Global Limited ($PRE).
- $PRE last traded around $20.51.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David Vanderveen, insider at Prenetics Global Limited ($PRE), sold 8,681 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Prenetics Global Limited Stock Down 20.4%
Shares of Prenetics Global Limited ($PRE) traded around $20.51 on Wednesday, down 20.4% for the day.
Prenetics Global Limited Earnings
Analysts Set New Price Targets
About Prenetics Global Limited
Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Get Prenetics Global Limited alerts
New 13F filings, insider trades, and analyst moves on $PRE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.